NUROFEN manufacturer Reckitt Benckiser (RB) will pay $3.5m compensation to consumers who, according to their class action, claim to have been misled by the company's Specific Pain range packaging.
The arrangement, managed by Banniser Law, is yet to be confirmed by the Federal Government Court.
A third party will distribute the funds to eligible consumers who purchased the products between 2011 and 2015 in the belief they were buying different products to relieve specific separate pain.
The original fine proposed for RB by the Federal Court was $1.7m (PD 29 Apr 16) in spite of ACCC and others such as Choice calling for a $6m fine (PD 13 Apr 16, 21 Dec 16).
RB New Zealand was fined $1m for its marketing of the Nurofen Specific Pain range (PD 07 Feb 17).
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Aug 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Aug 17
